Predictive, Preventative, personalized Medicine

Stanford Students in Biodesign's 2018 Research Conference


Predictive, Preventative, personalized Medicine

Stanford Students in Biodesign's 2018 Research Conference

Conference Overview

Join us for our conference Predictive, Preventive, Personalized Medicine! Hear from nine of the world's top scholars and researchers in the field of personalized medicine! Meet speakers promoting personalized medicine in research, industry, and public policy. Learn about new developments and trends as medicine uses genes to find the best treatments. 

Breakfast, lunch, and a special afternoon treat will be provided to those in attendance!

Date & Time: April 7, 9:30 AM - 5 PM
location: SHriram 104 Auditorium


Questions? Email Anjini Karthik ( or Chelsea Chen (


9:30 AM

10:00 AM

10:15 AM

10:50 AM

11:25 AM

11:55 AM

1:00 PM

1:35 PM

2:10 PM

2:35 PM

3:10 PM

3:45 PM

4:15 PM


Conference Registration and Morning Coffee Reception

Opening Remarks by Anjini Karthik '20 and Chelsea Chen '20, Event Organizing Leads

Remarks by Dean Lloyd Minor, MD

Remarks by Dr. Michael Zwick, PhD

Remarks by Charlotte Weaver

Break for Lunch

Remarks by Chris Lunt

Remarks by Dr. Lou Garrison, PhD

Break and refreshments

Remarks by Dr. Shuji Ogino, MD, PhD, MS

Remarks by Dr. Cynthia Morton, PhD

Remarks by Dr. Dan Anderson, PhD

Closing Remarks by Anjini and Chelsea





Dean Lloyd Minor, MD - Stanford University

Lloyd B. Minor, MD, is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine. With his leadership, Stanford Medicine has established a strategic vision to lead the biomedical revolution in Precision Health, a fundamental shift to more proactive and personalized health care that empowers people to lead healthy lives. Dr. Minor is also a professor of Otolaryngology–Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University. With more than 140 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders. In 2012, he was elected to the National Academy of Medicine.


Dr. Michael Zwick

Dr. Zwick is the Assistant Vice President for Research of the Robert W. Woodruff Health Sciences Center at Emory University and the Assistant Dean of Research and Associate Professor of Human Genetics and Pediatrics in the Emory University School of Medicine. Trained as an experimental population geneticist in both the Drosophila and human systems, he has substantial experience in generating and analyzing large genomic datasets used to identify rare genetic variation that contributes to pediatric disorders. Disorders studied include autism, congenital heart defects in children with Down Syndrome, inflammatory bowel disease, schizophrenia, and Fragile X. As Assistant Vice President for Research in the Robert W. Woodruff Health Sciences Center, Assistant Dean of Research in the Emory University School of Medicine, he leads the Emory Integrated Core Facilities (EICF, The EICF workforce includes 135 scientists and technical staff and directly supports Emory researchers with annual external research funding exceeding 628 million dollars.


Charlotte Weaver

Charlotte joined CZI in 2017. She is working on applications to visualize and analyze single cell RNA-seq data. Previously at Janelia Research Campus she contributed to software and web applications for many team projects, shared resources, and labs. She is co-founder of the Women's Coding Circle. She earned her Master’s degree in Bioinformatics from Georgia Tech in 2010 where she studied sigma factors of Bacillus anthracis using next-gen sequencing technologies. Prior to that she spent two years at NIH studying the neuro-protective effects of bipolar treatments on mice concurrent with earning her Bachelor's degree in Cell Molecular Biology and Genetics from the University of Maryland, College Park in 2007.


Chris Lunt

Chris Lunt is the CTO of the All of Us Research Program, an endeavor to collect comprehensive health information, including a full genome, for one million Americans. This information will be used to transform precision medicine. Chris has been a technology executive for nearly twenty years, having previously worked on public/private health insurance systems, crowd work, digital identity and social networks, and information ontologies. He is co-inventor of a dozen seminal social networking patents. He has started multiple companies, and has one IPO. He is an avid musician, writer, and reader.




Kathryn Phillips - Professor of Health Services Research and Health Economics, Founding Director, UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)

Dr. Phillips’s expertise is on the implementation of new technologies to improve healthcare. As founding director of the UCSF Center for Translational and Policy Research on Personalized Medicine, she focuses on access, quality, and value of precision/personalized medicine. Dr. Phillips has published ~150 articles in major journals, including JAMA, New England Journal of Medicine, and Health Affairs, and has had continuous funding from the NIH as a Principal Investigator for 25 years. She serves on the editorial boards of the journals Health Affairs and Value in Health as well as all of the leading journals on precision medicine. A distinguishing characteristic of Dr. Phillips’ work is the translation of science into policy by bringing together perspectives across stakeholders. She has worked extensively with health plans, industry, and government agencies across the globe and has served on national and international scientific advisory committees for the National Academy of Medicine, Food and Drug Administration, and the President’s Council of Advisors on Science and Technology. Dr. Phillips is now serving on the Board of Directors for GenomeCanada (the non-profit organization that oversees and funds all genomic research in Canada). In 2016, she was awarded a Rockefeller Foundation Bellagio Residency to pursue her work from a global perspective. Dr. Phillips holds degrees from UC-Berkeley, Harvard, and UT-Austin.



Dr. Shuji Ogino

Shuji Ogino, MD, PhD, MS, is Professor of Pathology at Brigham and Women’s Hospital (BWH), Dana-Farber Cancer Institute, Harvard Medical School; Professor (Epidemiology) at Harvard T.H. Chan School of Public Health; the founding Chief of Program in MPE Molecular Pathological Epidemiology at BWH; and Associate Member of Broad Institute of MIT and Harvard. Dr. Ogino has been developing the integrative transdisciplinary science of molecular pathological epidemiology (MPE), using colorectal cancer as a disease model. Dr. Ogino has been the Chairperson for The International MPE Meeting Series ( since 2013. With his unique viewpoints, he has created novel paradigms, research frameworks and models, including “GWAS-MPE approach”, “colorectal continuum model”, “unique disease principle”, “etiologic field effect model”, “lifecourse - MPE model”, "causal inference - MPE model", and “social – MPE model”. Recently, Dr. Ogino is further expanding realms of MPE, to integrate it with microbiology and immunology ("immuno-MPE") and pharmacology ("pharmaco-MPE"). Dr. Ogino has received a number of awards and honors, including Ramzi Cotran Young Investigator Award from United States and Canadian Academy of Pathology (USCAP); Executive Officer’s Award and Meritorious Service Award from Association for Molecular Pathology (AMP); recognitions of “Most Influential Scientific Minds” and/or "Highly Cited Researcher” from 2014 through 2017 by Thomson Reuters and Clarivate Analytics; Outstanding Investigator Award from American Society of Investigative Pathology (ASIP); elected membership in the American Society for Clinical Investigation (ASCI); membership of FASEB Excellence in Science Award Committee; and membership of various USA National Institutes of Health (NIH) study sections. Since 2015, Dr. Ogino has been a recipient of National Cancer Institute (NCI) R35 Outstanding Investigator Award, which represents 7-year funding to pursue paradigm-shifting high-impact research.



Dr. Cynthia Morton

Cynthia Casson Morton is the William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology and Professor of Pathology at Harvard Medical School, and the Kenneth J. Ryan, M.D. Distinguished Chair in Obstetrics and Gynecology and Director of Cytogenetics at Brigham and Women’s Hospital.  She received her Bachelor’s of Science degree from the College of William and Mary in Virginia and her Ph.D. in Human Genetics from the Medical College of Virginia in Richmond. As a human geneticist, Dr. Morton is interested in studying the genetic causes of hearing loss, uterine fibroids and birth defects so that new understanding of the biology of the disorders may be gained and new treatments developed.  She also is beginning a new study based at Brigham and Women’s Hospital and at the University of Manchester, UK called SEQaBOO (SEQuencing a Baby for an Optimal Outcome). These programs will integrate genomic sequencing into newborn screening for babies who fail their newborn hearing screening tests and evaluate clinical utility of genomic testing in the care of babies born with heritable hearing loss.


Dr. Dan Anderson

Professor Daniel G. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances and products in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. His work has resulted in the publication of over 400 papers, patents and patent applications. These patents were the basis for the foundation of a number of companies in the pharmaceutical, biotechnology, and consumer products space, and have led to a number of products that have been commercialized or are in clinical development.